| Literature DB >> 33907091 |
Guifen Xu1,2, Feizhen Chen3, Wenxiang Zhao1, Yong Zheng1, Wei Zhuang1, Fuling Yu1.
Abstract
ABSTRACT: We aimed to identify potential clinical predictors associated with the risk of fulminant myocarditis, and further to establish and assess a nomogram model based on significant attributes for clinical practicability.This is a retrospective, cross-sectional study, involving 28 patients with fulminant myocarditis and 35 age-, and sex-matched patients with non-fulminant myocarditis. Effect-size estimates are expressed as odds ratio (OR) and 95% confidence interval (CI).Fifteen factors were primarily identified to be associated with the significant risk of fulminant myocarditis after adjusting for confounders. Due to strong correlation, 6 factors were retained, including mean arterial pressure (OR, 95% CI, P: .82, .72-.94, .005), creatinine (2.15, 1.13-4.10, 0.020), blood urea nitrogen (1.45, 1.04-2.02, 0.028), aspartate aminotransferase (2.62, 1.16-5.91, 0.021), troponin I (1.43, 1.07-1.90, 0.015), and ventricular wall motion abnormality (25.81, 2.52-264.69, 0.006). The contribution of the 6 significant factors to predicting fulminant myocarditis risk was significant from multi-angle analyses, and regressing these factors in a nomogram model exhibited good predictive accuracy, as reflected by both C-index (>90%, P < .001).We have identified 6 clinical factors in significant association with fulminant myocarditis, and their prediction capability was more obvious in a nomogram model. Further investigations with larger sample sizes and longer follow-up intervals are warranted.Entities:
Mesh:
Substances:
Year: 2021 PMID: 33907091 PMCID: PMC8084052 DOI: 10.1097/MD.0000000000025317
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
The baseline characteristics of study subjects.
| Patients with FM | Patients with NFM | ||
| Characteristics | (n = 28) | (n = 35) | |
| Age, y | 47.5 (37, 63) | 48 (38, 69) | .63 |
| Males | 14 (50%) | 17 (49%) | .74 |
| Cigarette smoking | 9 (32.1%) | 11 (31.4%) | .93 |
| Alcohol drinking | 6 (21.4%) | 10 (28.6%) | .67 |
| MAP, mm Hg | 96.33 (82.67, 107) | 134 (122.67, 148) | <.01 |
| Pulse (per minute) | 82 (60, 96) | 80 (70, 90) | .78 |
| Laboratory biomarkers | |||
| WBC (×109/L) | 8.19 (7.37, 9.14) | 6.43 (5.27, 8.01) | .01 |
| Neutrophil percentage (%) | 82.35 (73.2, 85.8) | 66.6 (52.9, 73.1) | <.01 |
| Neutrophil count (×109/L) | 6.06 (5.43, 7.38) | 4.29 (3.05, 5.72) | <.01 |
| Lymphocyte count (×109/L) | 0.96 (0.82, 1.45) | 1.45 (1.05, 1.77) | .04 |
| Hemoglobin, g/L | 141.5 (127, 145) | 141 (131, 151) | .89 |
| Platelet (×109/L) | 213.5 (133, 222) | 214 (182, 231) | .26 |
| CRP, mg/L | 26.99 (11.23, 51.46) | 20.62 (5.46, 49.95) | .55 |
| Procalcitonin, ng/L | 0.19 (0.08, 0.8) | 0.07 (0.05, 0.18) | .04 |
| Blood glucose, mmol/L | 10.63 (7.02, 13.71) | 5.33 (4.48, 6.56) | <.01 |
| Kalium, mmol/L | 3.96 (3.76, 4.19) | 4.2 (3.87, 4.36) | .15 |
| Magnesium, mmol/L | 0.95 (0.88, 1.02) | 0.87 (0.82, 0.93) | .07 |
| Uric acid, μmol/L | 375.95 (261, 461) | 326.8 (249, 364.6) | .18 |
| Creatinine, μmol/L | 74 (56.6, 98.7) | 64 (61, 70.5) | .25 |
| BUN, mmol/L | 8.43 (4.92, 10.08) | 4.5 (3.9, 6.42) | <.01 |
| D-dimer, mg/L | 2.12 (0.8, 3.57) | 0.33 (0.21, 0.51) | <.01 |
| Fibrinogen, g/L | 3.56 (2.57, 4.15) | 3 (2.36, 3.84) | .36 |
| NT-proBNP, pg/mL | 8965 (5700, 21500) | 291 (82, 675.8) | <.01 |
| TNI, ng/mL | 4.35 (0.67, 8) | 0.77 (0.28, 1.6) | .01 |
| LDH, U/L | 556.5 (414, 863) | 245 (207, 288) | <.01 |
| Creatine kinase, U/L | 443.5 (114, 943) | 209 (83, 350) | .06 |
| CKMB, U/L | 59.5 (19, 77) | 21 (12, 31) | .02 |
| Total bilirubin, μmol/L | 12.3 (8, 18.7) | 10.3 (6.9, 13.8) | .21 |
| Direct bilirubin, μmol/L | 5.55 (3.4, 7) | 3.9 (2.9, 5.6) | .06 |
| Albumin, g/L | 38.5 (35.5, 40.6) | 38.2 (36.6, 41.7) | .48 |
| ALT, U/L | 101 (51, 140) | 23 (16, 43) | <.01 |
| AST, U/L | 138.5 (38, 254) | 34 (23, 48) | <.01 |
| Total cholesterol, mmol/L | 3.6 (3.32, 4.68) | 3.61 (3.16, 4.24) | .84 |
| Triglyceride, mmol/L | 0.89 (0.68, 1.33) | 1.06 (0.53, 1.39) | .81 |
| HDL, mmol/L | 0.95 (0.7, 1.27) | 1.05 (0.83, 1.22) | .47 |
| LDL, mmol/L | 2.52 (1.75, 3.13) | 2.1 (1.96, 2.63) | .30 |
| Echocardiographic indexes | |||
| LAD, cm | 3.52 (3.3, 3.98) | 3.58 (3.24, 3.90) | .99 |
| LVEDD, cm | 4.9 (4.32, 5.17) | 4.87 (4.61, 5.01) | .84 |
| IVST, cm | 1.13 (1.02, 1.29) | 0.89 (0.82, 0.94) | <.01 |
| IVPWT, cm | 0.98 (0.91, 1.13) | 0.79 (0.72, 0.84) | <.01 |
| SV, mL | 51.63 (45.66, 63.36) | 72.09 (66.81, 79.73) | <.01 |
| LVEF (%) | 50.13 (38.1, 58.43) | 67.16 (62.7, 70.06) | <.01 |
| VWMA | 16 (57.1%) | 2 (5.7%) | <.01 |
Identification of significant factors for the risk of fulminant myocarditis before and after adjustment.
| Unadjusted model | Adjusted model∗ | |||||
| Significant factors | OR | 95% CI | OR | 95% CI | ||
| MAP | 0.82 | (0.72–0.94) | .004 | 0.82 | (0.72–0.94) | .005 |
| Blood glucose | 1.76 | (1.25–2.48) | .001 | 1.99 | (1.24–3.20) | .005 |
| D-dimer | 4.89 | (1.64–14.58) | .004 | 5.90 | (1.65–21.34) | .006 |
| Creatinine (per 10 increment) | 1.46 | (0.99–2.16) | .053 | 2.15 | (1.13–4.10) | .020 |
| BUN | 1.55 | (1.13–2.12) | .006 | 1.45 | (1.04–2.02) | .028 |
| AST (per 50 increment) | 2.32 | (1.23–4.69) | .010 | 2.62 | (1.16–5.91) | .021 |
| Troponin I | 1.43 | (1.09–1.88) | .010 | 1.43 | (1.07–1.90) | .015 |
| LDH (per 100 increment) | 2.91 | (1.50–5.62) | .002 | 3.44 | (1.48–7.96) | .004 |
| Creatine kinase (per 20 increment) | 2.14 | (1.05–4.65) | .035 | 4.64 | (1.28–16.84) | .020 |
| CKMB (per 10 increment) | 1.63 | (1.15–2.31) | .006 | 1.85 | (1.14–3.00) | .013 |
| IVST (per 0.1 increment) | 5.22 | (1.92–14.15) | .001 | 14.32 | (2.33–88.18) | .004 |
| IVPWT (per 0.1 increment) | 6.08 | (1.94–19.03) | .002 | 5.53 | (1.82–16.86) | .003 |
| SV | 0.87 | (0.81–0.95) | .001 | 0.85 | (0.76–0.95) | .003 |
| LVEF | 0.81 | (0.71–0.92) | .001 | 0.81 | (0.70–0.93) | .003 |
| VWMA | 30.00 | (3.31–272.34) | .003 | 25.81 | (2.52–264.69) | .006 |
Prediction accuracy gained by adding significant factors identified to basic model in predicting fulminant myocarditis risk.
| Statistics | Basic model | Full model |
| AIC | 38.35 | 55.96 |
| BIC | 50.05 | 77.85 |
| HL test ( | 0.881 | 0.953 |
| LR test ( | 0.011 | |
| NRI ( | 0.008 | |
| IDI ( | <0.001 | |
| AUROC ( | 0.019 |
Figure 1Decision curve analysis on the net benefits of adding significant uncorrelated factors to the basic model.
Figure 2The prediction nomogram model for fulminant myocarditis. AST = aspartate aminotransferase, BUN = blood urea nitrogen, MAP = mean arterial pressure, TNI = Troponin I, VWMA = ventricular wall motion abnormality.
Figure 3Changes of predictive echocardiographic measurements during follow-ups. M = fulminant myocarditis, IVPWT = left ventricular posterior wall thickness, LVEF = left ventricular ejection fraction, NFM = non-fulminant myocarditis, SV = stroke volume.